Review



tlr9 agonist 166  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress tlr9 agonist 166
    Tlr9 Agonist 166, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/ODN+1018/pm41791624-84-0-9
    Average 94 stars, based on 1 article reviews
    tlr9 agonist 166 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Marker:

    Article Title: STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Article Snippet: 6–8 weeks old, were subcutaneously immunized with various free or LNP-encapsulated peptides, with or without free or LNP-encapsulated diABZI, free poly-I:C (tlrl-pic, InvivoGen), ODN1018 (HY-150724C, MCE) or ISCOMs, serving as controls or benchmarks. Peptides and diABZI were used at 10 nmol per mouse. Poly-I:C, ODN1018 and ISCOMs were used at 10 μg per mouse. Other mice were subcutaneously immuniz

    Membrane:

    Article Title: STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Article Snippet: 6–8 weeks old, were subcutaneously immunized with various free or LNP-encapsulated peptides, with or without free or LNP-encapsulated diABZI, free poly-I:C (tlrl-pic, InvivoGen), ODN1018 (HY-150724C, MCE) or ISCOMs, serving as controls or benchmarks. Peptides and diABZI were used at 10 nmol per mouse. Poly-I:C, ODN1018 and ISCOMs were used at 10 μg per mouse. Other mice were subcutaneously immuniz

    Mass Spectrometry:

    Article Title: STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Article Snippet: 6–8 weeks old, were subcutaneously immunized with various free or LNP-encapsulated peptides, with or without free or LNP-encapsulated diABZI, free poly-I:C (tlrl-pic, InvivoGen), ODN1018 (HY-150724C, MCE) or ISCOMs, serving as controls or benchmarks. Peptides and diABZI were used at 10 nmol per mouse. Poly-I:C, ODN1018 and ISCOMs were used at 10 μg per mouse. Other mice were subcutaneously immuniz

    High Performance Liquid Chromatography:

    Article Title: STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Article Snippet: 6–8 weeks old, were subcutaneously immunized with various free or LNP-encapsulated peptides, with or without free or LNP-encapsulated diABZI, free poly-I:C (tlrl-pic, InvivoGen), ODN1018 (HY-150724C, MCE) or ISCOMs, serving as controls or benchmarks. Peptides and diABZI were used at 10 nmol per mouse. Poly-I:C, ODN1018 and ISCOMs were used at 10 μg per mouse. Other mice were subcutaneously immuniz

    Mouse Assay:

    Article Title: STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Article Snippet: 6–8 weeks old, were subcutaneously immunized with various free or LNP-encapsulated peptides, with or without free or LNP-encapsulated diABZI, free poly-I:C (tlrl-pic, InvivoGen), ODN1018 (HY-150724C, MCE) or ISCOMs, serving as controls or benchmarks. Peptides and diABZI were used at 10 nmol per mouse. Poly-I:C, ODN1018 and ISCOMs were used at 10 μg per mouse. Other mice were subcutaneously immuniz



    Similar Products

    tlr9 agonist 166  (MedChemExpress)
    94
    MedChemExpress tlr9 agonist 166
    Tlr9 Agonist 166, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/ODN+1018/pm41791624-84-0-9
    Average 94 stars, based on 1 article reviews
    tlr9 agonist 166 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    class b cpg odn  (InvivoGen)
    94
    InvivoGen class b cpg odn
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Class B Cpg Odn, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/ODN+1018+VacciGrade/pmc13260544-43-11-15
    Average 94 stars, based on 1 article reviews
    class b cpg odn - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    odn 1018 vaccigrade  (InvivoGen)
    94
    InvivoGen odn 1018 vaccigrade
    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
    Odn 1018 Vaccigrade, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/ODN+1018+VacciGrade/pm42066777-352-25-28
    Average 94 stars, based on 1 article reviews
    odn 1018 vaccigrade - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    odn 1018 vaccigradetm  (InvivoGen)
    94
    InvivoGen odn 1018 vaccigradetm
    Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
    Odn 1018 Vaccigradetm, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/ODN+1018+VacciGrade/pmc13124971-89-24-36
    Average 94 stars, based on 1 article reviews
    odn 1018 vaccigradetm - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cpg odn 1018s  (Sangon Biotech)
    86
    Sangon Biotech cpg odn 1018s
    Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
    Cpg Odn 1018s, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/1018s+cpg/pmc12474238-57-1-11
    Average 86 stars, based on 1 article reviews
    cpg odn 1018s - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    cpg 1018® (cpg odn 1018) adjuvant  (Dynavax Technologies)
    90
    Dynavax Technologies cpg 1018® (cpg odn 1018) adjuvant
    Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
    Cpg 1018® (Cpg Odn 1018) Adjuvant, supplied by Dynavax Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/cpg+1018/us12364745-169-10-2
    Average 90 stars, based on 1 article reviews
    cpg 1018® (cpg odn 1018) adjuvant - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    cpg odn 1018s adjuvant  (Sangon Biotech)
    90
    Sangon Biotech cpg odn 1018s adjuvant
    Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
    Cpg Odn 1018s Adjuvant, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/cpg+1018s/pm40354699-69-1-8
    Average 90 stars, based on 1 article reviews
    cpg odn 1018s adjuvant - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    odn1018  (MedChemExpress)
    94
    MedChemExpress odn1018
    Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
    Odn1018, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/odn+1018/ODN+1018/pm40140567-591-25-27
    Average 94 stars, based on 1 article reviews
    odn1018 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG ODN, and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.

    Journal: Frontiers in Immunology

    Article Title: Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide

    doi: 10.3389/fimmu.2026.1824741

    Figure Lengend Snippet: Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG ODN, and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.

    Article Snippet: The adjuvant used in this study was CpG ODN 1018, a class B CpG ODN (InvivoGen, San Diego, CA, USA; cat. vac-1018-1), with the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′.

    Techniques: Expressing, CCK-8 Assay, Control

    Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Journal: Frontiers in Immunology

    Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

    doi: 10.3389/fimmu.2026.1787216

    Figure Lengend Snippet: Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

    Techniques: Injection, Enzyme-linked Immunosorbent Assay, Adjuvant

    Administration of antigen formulated using ALTA ® platform elicits antibody subtypes that align with a balanced Th1/Th2 response. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice were boosted at week 6. Shown are the anti-OVA IgG2c titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I) . (A) Anti-OVA IgG2c titers (log10) over 12 weeks and (B) the GMR at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG2c titers (log10) over 12 weeks and (D) the GMR at week 4 (n = 5) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG2c titers (log10) before and after boost at week 6 and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG2c titers (log10) before and after boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG2c (log10) at week 26 after one or two doses of 62.5 ng OVA/dose (n = 4–5) or 250 ng OVA/dose (n = 3–5). (J) The ratio of IgG2c (log10) to IgG1 (log10) at week 10 (1,000 ng OVA/dose, n = 3–5/group). Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant; GMR, geometric mean ratio.

    Journal: Frontiers in Immunology

    Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

    doi: 10.3389/fimmu.2026.1787216

    Figure Lengend Snippet: Administration of antigen formulated using ALTA ® platform elicits antibody subtypes that align with a balanced Th1/Th2 response. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice were boosted at week 6. Shown are the anti-OVA IgG2c titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I) . (A) Anti-OVA IgG2c titers (log10) over 12 weeks and (B) the GMR at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG2c titers (log10) over 12 weeks and (D) the GMR at week 4 (n = 5) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG2c titers (log10) before and after boost at week 6 and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG2c titers (log10) before and after boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG2c (log10) at week 26 after one or two doses of 62.5 ng OVA/dose (n = 4–5) or 250 ng OVA/dose (n = 3–5). (J) The ratio of IgG2c (log10) to IgG1 (log10) at week 10 (1,000 ng OVA/dose, n = 3–5/group). Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant; GMR, geometric mean ratio.

    Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

    Techniques: Injection, Enzyme-linked Immunosorbent Assay, Adjuvant

    Administration of antigen formulated using ALTA ® platform elicits a more robust antigen (OVA)-specific CD8+ T-cell response than Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. C57BL/6 mice were i.m. immunized with 62.5 or 250 ng of OVA antigen delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Blood was collected at the indicated time points after prime (A–E) or boost (week 6) (F–H) and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry. (A) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells of total CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 2 post-vaccination. (B, C) The frequency of OVA-specific CD8+ T cells in blood at weeks 1, 2, 4, 8, and 10 after vaccinations with 62.5 (B) or 250 ng (C) OVA. The percentage of CD127 (IL-7Rα) and/or KLRG1-expressing (D) and Granzyme B+ (E) within OVA-specific CD8+ T cells after ALTA ® vaccination (250 ng OVA). (F) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 8 after prime (top row) and 2 weeks after boost (bottom row). The frequency of OVA-specific CD8+ T cells at week 8 after prime and 2 weeks after week 6 boost with 250 ng (G) and 62.5 ng OVA (H) . Shown are the representative data from one of two [ (A–E) : ALTA ® and Alhydrogel ® groups] or one experiment [ (A–D) : AddaVax™ and Alhydrogel ® + CpG ODN 1018 groups; (F–H) : all groups]. N = 4–10/group. Mean ± SEM. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Journal: Frontiers in Immunology

    Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

    doi: 10.3389/fimmu.2026.1787216

    Figure Lengend Snippet: Administration of antigen formulated using ALTA ® platform elicits a more robust antigen (OVA)-specific CD8+ T-cell response than Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. C57BL/6 mice were i.m. immunized with 62.5 or 250 ng of OVA antigen delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Blood was collected at the indicated time points after prime (A–E) or boost (week 6) (F–H) and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry. (A) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells of total CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 2 post-vaccination. (B, C) The frequency of OVA-specific CD8+ T cells in blood at weeks 1, 2, 4, 8, and 10 after vaccinations with 62.5 (B) or 250 ng (C) OVA. The percentage of CD127 (IL-7Rα) and/or KLRG1-expressing (D) and Granzyme B+ (E) within OVA-specific CD8+ T cells after ALTA ® vaccination (250 ng OVA). (F) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 8 after prime (top row) and 2 weeks after boost (bottom row). The frequency of OVA-specific CD8+ T cells at week 8 after prime and 2 weeks after week 6 boost with 250 ng (G) and 62.5 ng OVA (H) . Shown are the representative data from one of two [ (A–E) : ALTA ® and Alhydrogel ® groups] or one experiment [ (A–D) : AddaVax™ and Alhydrogel ® + CpG ODN 1018 groups; (F–H) : all groups]. N = 4–10/group. Mean ± SEM. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

    Techniques: Flow Cytometry, Expressing, Adjuvant

    The frequency and numbers of the total and cytokine-producing OVA-specific CD8+ T cells in the spleens are increased after ALTA ® immunization. C57BL/6 mice were i.m. immunized with 1,000 ng of OVA delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Indicated groups were boosted at week 6 after prime. (A–D) The spleens were collected at week 14 after prime and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD44+CD8α+CD19− live lymphocytes). (A) The percentage of OVA-specific CD8+ T cells of total CD8+ T cells. (B) The total number of OVA-specific CD8+ T cells per spleen. (C) The percentage and number (D) of CD127 (IL-7Rα) and/or KLRG1-expressing OVA-specific CD8+ T cells after ALTA ® OVA vaccination. (E–H) The splenocytes were re-stimulated with the OVA peptide pool for 5 h ex vivo , and the expression of IFN-γ, IL-2, and/or TNF-α was measured via intracellular cytokine staining. (E, F) The frequency (E) and number per spleen (F) of the CD8+ T cells expressing IFN-γ, IL-2, or TNF-α (gated as CD44+CD8α+CD19− live lymphocytes). (G, H) The frequency (G) and number per spleen (H) of the CD8+ T cells expressing two cytokines (IFN-γ+IL-2+, IFN-γ+TNF-α+, and IL-2+TNF-α+). N = 3–5/group. Mean ± SEM. Brown–Forsythe and Welch’s ANOVA Dunnett’s T3 multiple comparisons test between ALTA ® and other groups (at matching number of doses). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Journal: Frontiers in Immunology

    Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

    doi: 10.3389/fimmu.2026.1787216

    Figure Lengend Snippet: The frequency and numbers of the total and cytokine-producing OVA-specific CD8+ T cells in the spleens are increased after ALTA ® immunization. C57BL/6 mice were i.m. immunized with 1,000 ng of OVA delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Indicated groups were boosted at week 6 after prime. (A–D) The spleens were collected at week 14 after prime and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD44+CD8α+CD19− live lymphocytes). (A) The percentage of OVA-specific CD8+ T cells of total CD8+ T cells. (B) The total number of OVA-specific CD8+ T cells per spleen. (C) The percentage and number (D) of CD127 (IL-7Rα) and/or KLRG1-expressing OVA-specific CD8+ T cells after ALTA ® OVA vaccination. (E–H) The splenocytes were re-stimulated with the OVA peptide pool for 5 h ex vivo , and the expression of IFN-γ, IL-2, and/or TNF-α was measured via intracellular cytokine staining. (E, F) The frequency (E) and number per spleen (F) of the CD8+ T cells expressing IFN-γ, IL-2, or TNF-α (gated as CD44+CD8α+CD19− live lymphocytes). (G, H) The frequency (G) and number per spleen (H) of the CD8+ T cells expressing two cytokines (IFN-γ+IL-2+, IFN-γ+TNF-α+, and IL-2+TNF-α+). N = 3–5/group. Mean ± SEM. Brown–Forsythe and Welch’s ANOVA Dunnett’s T3 multiple comparisons test between ALTA ® and other groups (at matching number of doses). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

    Techniques: Flow Cytometry, Expressing, Ex Vivo, Staining, Adjuvant

    ALTA ® platform is antigen- and aluminum-sparing. C57BL/6 mice were i.m. immunized with 62.5, 250, or 1,000 ng of OVA antigen per dose delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Where indicated, the boost doses were administered at week 6 after prime. (A, B) Shown are the total OVA doses (ng) (X axis) by the mean anti-OVA IgG1 (log10) titers (Y axis) at week 4 after prime (A) and week 4 after boost (B) . The amount of aluminum (ng Al3+) delivered with each treatment is indicated as a color-coded number on the graph. The AddaVax™ group did not receive any aluminum and is labeled as “n/a” (not applicable). (C, D) Shown are the total OVA doses (ng) (X axis) by the mean percentage of the OVA-specific CD8+ T cells in blood (Y axis) at week 2 after prime (C) and week 2 after boost. (D) N = 4–5/group. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Journal: Frontiers in Immunology

    Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

    doi: 10.3389/fimmu.2026.1787216

    Figure Lengend Snippet: ALTA ® platform is antigen- and aluminum-sparing. C57BL/6 mice were i.m. immunized with 62.5, 250, or 1,000 ng of OVA antigen per dose delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Where indicated, the boost doses were administered at week 6 after prime. (A, B) Shown are the total OVA doses (ng) (X axis) by the mean anti-OVA IgG1 (log10) titers (Y axis) at week 4 after prime (A) and week 4 after boost (B) . The amount of aluminum (ng Al3+) delivered with each treatment is indicated as a color-coded number on the graph. The AddaVax™ group did not receive any aluminum and is labeled as “n/a” (not applicable). (C, D) Shown are the total OVA doses (ng) (X axis) by the mean percentage of the OVA-specific CD8+ T cells in blood (Y axis) at week 2 after prime (C) and week 2 after boost. (D) N = 4–5/group. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

    Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

    Techniques: Labeling, Adjuvant